Results 131 to 140 of about 53,176 (324)

Safety of 12‐Months Administration of Ashwagandha (Withania somnifera) Standardized Root Extract in Healthy Adults: A Prospective, Observational Study

Phytotherapy Research, EarlyView.
ABSTRACT Ashwagandha, an adaptogen, is an important herb of Ayurveda used as a Rasayana for its various health benefits. This prospective, multi‐center, observational clinical study evaluates the safety (clinical and laboratory) of a standardized Ashwagandha Root Extract (ARE) on long‐term administration over 12 months. Male and female adults (N = 191)
Jaising Salve, Sanjeev Kale, Banwari Lal Prajapati, Adele Sparavigna, Mark Savant, John Ademola, Deepak Langade   +6 more
wiley   +1 more source

How do index patients participating in genetic screening programmes for familial hypercholesterolemia (FH) interpret their DNA results?:A UK-based qualitative interview study [PDF]

, 2011
Douglas, Margaret, Finnie, Robert, Hallowell, Nina, Jenkins, Nick, Lawton, Julia, Porteous, Mary, Walker, Simon   +6 more
core   +1 more source

Staging concept for aging management: Definition, mechanism, and coping strategies

VIEW, EarlyView.
We divided the overall aging stage into “pre‐aging”, “aging compensation”, and “aging disability”. For each stage, we delineate the clinical presentations, biological phenomena, theoretical underpinnings, and key management priorities. Abstract Aging, as a gradual and largely irreversible biological process, characterized by declining organismal ...
Zhonghan Wang, Shixian Liu, Shangyu Du, Xiangran Cui, Bo Chao, Minglei Liu, Minfei Wu   +6 more
wiley   +1 more source

Rheumatoid-like hand deformities and aortic valve disease in a 13-year-old girl with homozygous familial hypercholesterolemia: a case report

Journal of Medical Case Reports
Background Familial hypercholesterolemia is an autosomal dominant disorder characterized by elevated serum low-density lipoprotein cholesterol levels, tendon xanthomas, and an increased risk of atherosclerotic heart disease.
Anjuman Ara Rahman, Abhijit Datta, Kamal Uddin Ahmed, Anindita Das Barshan, Mohammad Jahid Hasan   +4 more
doaj   +1 more source

Life Course Approach for Managing Familial Hypercholesterolemia

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Treatment of familial hypercholesterolemia is directed toward the moment of the medical encounter. However, risk for heart disease as a consequence of having familial hypercholesterolemia is related to lifelong exposure to elevated low‐density ...
Samuel S. Gidding, Dirk J. Blom, Brian McCrindle, Uma Ramaswami, Raul D. Santos, Gerald F. Watts, Albert Wiegman   +6 more
doaj   +1 more source

Low-density lipoprotein cholesterol lowering therapies: what is on the horizon? [PDF]

, 2015
Elevated low-density lipoprotein cholesterol (LDL-C) levels are associated with an increased risk for cardiovascular disease (CVD). Statins have been the cornerstone of lipid therapy to lower LDL-C for the past two decades, but despite significant ...
Figueredo, M.D., Vincent M, Gadi, Ramprasad   +1 more
core   +1 more source

Diagnosis of Familial Hypercholesterolemia in Children and Young Adults [PDF]

, 2023
О. В. Тимощенко, Д. Е. Иванощук, Sergey Semaev, П. С. Орлов, Valentina Zorina, Е. В. Шахтшнейдер   +5 more
openalex   +1 more source

Circulating Musclin is associated with skeletal muscle function and subclinical cardiac dysfunction in patients with cancer

British Journal of Pharmacology, EarlyView.
Background and Purpose Musclin (osteocrin) is a skeletal muscle‐derived peptide that has been implicated in cardioprotective signalling pathways. Its relevance in cancer patients, who frequently experience muscle wasting and cardiotoxicity, remains unclear. This study aimed to determine whether circulating Musclin levels reflect functional capacity and
Jannek Brauer, Daniel Finke, Sebastian Romann, Norbert Frey, Joerg Heineke, Lorenz H. Lehmann   +5 more
wiley   +1 more source

Safety and Effectiveness of Low‐Density Lipoprotein Cholesterol–Lowering Therapy With Evolocumab for Familial Hypercholesterolemia/Hypercholesterolemia in Japan: A Real‐World, Postmarketing, Single‐Arm Study

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Evolocumab is the first monoclonal antibody against proprotein convertase subtilisin/kexin type 9 approved in Japan for familial hypercholesterolemia (FH) and hypercholesterolemia; however, data on its safety and effectiveness in the real ...
Koutaro Yokote, Junya Ako, Kazuo Kitagawa, Nobuhiro Osada, Feng Sheng, Masae Sonoda, Tamio Teramoto   +6 more
doaj   +1 more source

Familial hypercholesterolemia

Clinica Chimica Acta, 1971
Kehayoglou, K.A., Karli, N.J., Kiriazidis, K.J., Theodossiou, A.   +3 more
openaire   +3 more sources